Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Temodar-Resistant Malignant Glioma

NCT00613093 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT00613093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00613093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Temodar-Resistant Malignant Glioma
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2002
Completion date
August 31, 2008
Enrollment
67 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic glioma, glioblastoma multiforme